MHRA AI Airlock (2024)
The MHRA AI Airlock, launched May 2024, is a regulatory sandbox for AI as a Medical Device (AIaMD). Selected products work directly with the MHRA, Approved Bodies and the four UK home-nation health systems to stress-test regulatory questions that don't yet have settled answers — change control for adaptive models, real-world performance monitoring, bias and equity, and human-AI interaction.
On this page · 9 sections
How does MHRA AI Airlock (2024) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What the Airlock is
The AI Airlock is not a new regulatory regime. It is a sandbox: a controlled environment where the MHRA, an Approved Body and an AIaMD manufacturer co-develop the regulatory framing for a specific product whose features (adaptive learning, generative output, novel evidence base) fall outside settled guidance. Lessons learned feed back into future guidance and into the UK's wider Software and AI as a Medical Device Change Programme.
02Scope
- AIaMD candidates with novel regulatory challenges — adaptive models, generative AI outputs, agentic workflows, foundation-model-derived products.
- Products with a clear intended UK deployment pathway in NHS England, NHS Scotland, NHS Wales or HSC Northern Ireland.
- Manufacturers with a credible Quality Management System (typically ISO 13485) and existing or planned UKCA marking strategy.
03What it tests
- Intended purpose articulation — particularly hard for generative or agentic AIaMD where outputs are not bounded.
- Change control for learning models — when does a model update become a 'significant change' triggering reassessment?
- Real-world performance monitoring — what metrics, what cadence, what action thresholds.
- Bias, equity and fairness — how to detect and mitigate population-subgroup performance drift.
- Human-AI interaction — over-reliance, automation bias, alert fatigue, override logging.
- Cybersecurity and model-integrity attacks — prompt injection, training-data poisoning.
04Structure
The pilot ran a competitive selection in 2024 and confirmed candidates work with a dedicated MHRA Airlock Team and one of the Approved Bodies (BSI, DEKRA, SGS, TÜV SÜD, UL). Each candidate has a defined sandbox scope, success criteria, and a publication plan so the wider sector can learn from the case study.
05What it isn't
- Not a fast-track UKCA approval — Airlock participation does not waive any regulatory requirement.
- Not a clinical trial sandbox — clinical investigations remain under the Medicines for Human Use (Clinical Trials) Regulations and MHRA device-trial pathways.
- Not a substitute for the underlying QMS — manufacturers still need ISO 13485 and IEC 62304 discipline.
- Not a permanent programme by default — the pilot is structured to inform statutory and guidance change.
06Relationship to UK statutory reform
The UK is reforming its medical-device statute (UK MDR 2002 as amended) under the SaMD Change Programme. The Airlock generates evidence and case-study learning that feeds the reform — particularly on pre-authorised change control (UK equivalent to FDA's PCCP), real-world performance monitoring requirements, and equity expectations. Manufacturers operating in the Airlock get earlier sight of where the regulator's thinking is heading.
07Comparison with FDA and EU approaches
| Topic | UK (MHRA Airlock) | US (FDA) | EU |
|---|---|---|---|
| Sandbox/co-development | Yes — Airlock | Limited — Pre-Sub Q-Sub, CDRH digital health advisory | No formal sandbox; AI Act regulatory sandboxes emerging |
| Pre-authorised change | Under development via Airlock learning | PCCP (Predetermined Change Control Plan) guidance 2024 | Open question under MDR/IVDR; AI Act adds requirements |
| RWPM expectations | Being defined | FDA guidance under development; CDRH RWE program | MDR PMS / PMCF framework plus AI Act post-market monitoring |
| Equity/bias | Explicit Airlock workstream | FDA bias mitigation guidance under development | AI Act fundamental-rights impact assessment |
08Manufacturer implications
- If the product is genuinely novel and a UK launch is in plan, Airlock is the cheapest way to de-risk the regulatory pathway.
- Even if not selected, the published case-study output is the best read on where MHRA expectations are going.
- Quality system, intended-purpose articulation, change-control SOP and real-world performance monitoring framework all need to be in mature shape to participate productively.
- Cross-jurisdictional manufacturers should map Airlock outputs to FDA PCCP and the EU AI Act so a single technical-file artefact serves all three regimes.
09How V5 handles this
Frequently asked questions
Q.Is Airlock participation public?+
Yes — selected candidates are announced and case-study learning is published. Manufacturers who need to keep product details confidential can work with the Airlock team to scope what is published.
Q.Does Airlock cover IVDs?+
AIaMD in scope includes software qualified as a medical device or in vitro diagnostic medical device under the UK MDR 2002. IVD AI products are eligible.
Q.Does Airlock give UKCA marking?+
No. UKCA marking still requires the full conformity-assessment route. Airlock helps the manufacturer and the Approved Body align on novel regulatory questions before formal assessment.
Q.How does Airlock interact with the EU AI Act?+
The Airlock is UK-specific. Manufacturers selling into both UK and EU must satisfy both regimes; Airlock learning helps articulate intended purpose, change control and post-market monitoring that can be reused in EU technical documentation.
Primary sources
Further reading
Want to see how MHRA AI Airlock (2024) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.